ABOUT US SCIENCE PIPELINE PATIENTS & CAREGIVERS INVESTORS/MEDIA INSIDE SIGILON Addressing a broad range of chronic diseases Our Shielded Living TherapeuticsTM platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our products to produce a wide range of therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies and enzymes. Our pipeline currently spans three disease areas – including rare blood, lysosomal, and endocrine diseases – with product candidates designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression. Based on earlier preclinical data, we believe that SIG-001, our lead product candidate, has the potential to prevent bleeding episodes in patients with moderate-severe to severe hemophilia A by continuously secreting human FVIII. We are currently enrolling patients in a Phase 1/2 trial in this indication, as we continue to advance our other programs toward the clinic. PROGRAM DISCOVERY LEAD OPTIMIZATION IND ENABLING PHASE 1/2 PHASE 3 Rare Blood Disorders SIG-001 - Hemophilia A SIG-009 - FVII Deficiency SIG-003 - Hemophilia B Lysosomal Diseases SIG-005 - MPS-1 SIG-007 - Fabry SIG-018 - MPS-2 SIG-020 - MPS-6 Endocrine & Other Chronic Diseases SIG-002 - Type 1 Diabetes* SIG-XXX - IMD (Undisclosed) Platform could be foundation for multiple products to enable treatment of vast array of disorders that require chronic protein administration *Sigilon is leading execution of the program through IND and Eli Lilly and Company (Lilly), a global leader in diabetes, will develop and commercialize the program worldwide. ©2021 Sigilon Therapeutics, Inc. The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners. Privacy Policy